[HTML][HTML] First-line ICI monotherapies for advanced non-small-cell lung cancer patients with PD-L1 of at least 50%: A cost-effectiveness analysis
Q Liu, Z Zhou, X Luo, L Yi, L Peng, X Wan… - Frontiers in …, 2021 - frontiersin.org
Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and
cemiplimab, have been successively approved as first-line treatments for advanced non …
cemiplimab, have been successively approved as first-line treatments for advanced non …
[HTML][HTML] First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
Q Liu, Z Zhou, X Luo, L Yi, L Peng, X Wan… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and
cemiplimab, have been successively approved as first-line treatments for advanced non …
cemiplimab, have been successively approved as first-line treatments for advanced non …
First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
Q Liu, Z Zhou, X Luo, L Yi, L Peng… - Frontiers in …, 2021 - research.monash.edu
Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and
cemiplimab, have been successively approved as first-line treatments for advanced non …
cemiplimab, have been successively approved as first-line treatments for advanced non …
First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.
Q Liu, Z Zhou, X Luo, L Yi, L Peng, X Wan… - Frontiers in …, 2021 - europepmc.org
Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and
cemiplimab, have been successively approved as first-line treatments for advanced non …
cemiplimab, have been successively approved as first-line treatments for advanced non …
First-line ICI monotherapies for advanced non-small-cell lung cancer patients with PD-L1 of at least 50%: A cost-effectiveness analysis
Q Liu, Z Zhou, X Luo, L Yi, L Peng, X Wan, C Tan… - 2021 - figshare.utas.edu.au
Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and
cemiplimab, have been successively approved as first-line treatments for advanced non …
cemiplimab, have been successively approved as first-line treatments for advanced non …
First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
Q Liu, Z Zhou, X Luo, L Yi, L Peng… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and
cemiplimab, have been successively approved as first-line treatments for advanced non …
cemiplimab, have been successively approved as first-line treatments for advanced non …
[PDF][PDF] First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis. Front. Pharmacol …
Q Liu, Z Zhou, X Luo, L Yi, L Peng… - Frontiers in …, 2021 - figshare.utas.edu.au
Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and
cemiplimab, have been successively approved as first-line treatments for advanced …
cemiplimab, have been successively approved as first-line treatments for advanced …